MapLight Therapeutics Focuses $150 Million on Phase 3 Trial for ML-007C-MA
Capital Concentrated on Late-Stage Clinical Asset
MapLight Therapeutics (MPLT) is concentrating its resources on the additional pivotal trial for ML-007C-MA, a candidate for schizophrenia, after discontinuing pre-clinical and early-stage drug discovery investments. ML-007C-MA is an oral fixed-dose combination of betovumeline (ML-007) and fesoterodine, designed to activate central M1 and M4 muscarinic receptors while acting as a peripheral anticholinergic to reduce cholinergic side effects. Pre-clinical candidate ML-055 was a next-generation M1/M4 agonist, but the company opted to allocate funds to a lead candidate with a more defined regulatory pathway rather than an asset still in pre-clinical stages.
Efficacy and Dosage Regimen Risks Revealed by ZEPHYR
In the Phase 2 ZEPHYR trial, which involved 307 patients, the ML-007C-MA 210mg/3mg twice-daily group showed a 4.5-point improvement in PANSS total score compared to placebo at week 5, meeting the primary endpoint with an effect size of 0.37 and a p-value of 0.015. However, the 330mg/6mg once-daily group did not achieve statistical significance, weakening the rationale for developing a more convenient dosage regimen. The company plans to conduct an additional pivotal trial following an FDA Phase 2 end-of-trial meeting, with a target topline data readout in 2028. Thus, while development potential remains, the compliance and reproducible efficacy of the twice-daily regimen are key variables for the company's valuation.
Pipeline Reduction and Financial Defense
ML-004, which failed to meet the primary endpoint in the Phase 2 IRIS trial for autism spectrum disorder, is a zolmitriptan extended-release formulation targeting 5-HT1B/1D receptors. MapLight is seeking external licensing or collaboration opportunities for this asset instead of independent development and has halted early-stage research expenditures, including those for ML-009, ML-021, and ML-055. In addition, the company raised $150 million through a private stock offering, increasing its cash, cash equivalents, and investment assets to $351.3 million as of June 30, 2026. These funds are designed to support operations, including the pivotal trial for schizophrenia and the Phase 2 VISTA trial for Alzheimer's disease-related psychosis, through the end of 2028.
Cobenfi and Direclidine Set Competitive Benchmarks
Bristol Myers Squibb's (BMY) Cobenfi (xanomeline/trospium chloride) received FDA approval on September 26, 2024, and is the first marketed cholinergic treatment for schizophrenia. Unlike existing standard treatments such as risperidone, olanzapine, and aripiprazole, which are D2-based antipsychotics, it has validated the muscarinic pathway. The global schizophrenia treatment market was estimated at $9.08 billion in 2025. Neurocrine Biosciences' (NBIX) selective M4 agonist, direclidine (NBI-1117568), has entered Phase 3 trials, while AbbVie's (ABBV) M4-positive allosteric modulator, emraclidine, failed to achieve the primary endpoint in two Phase 2 trials. Therefore, MapLight's key challenge is to demonstrate superior tolerability and ease of administration compared to Cobenfi while also catching up to Direclidine's more advanced development timeline.
The twice-daily regimen in the ZEPHYR trial achieved a 4.5-point improvement in PANSS compared to placebo, with an effect size of 0.37 and a p-value of 0.015, but the failure of the once-daily regimen raises concerns about dosage regimen competitiveness and the reproducibility of results in Phase 3 trials. The $150 million private stock offering and existing cash, cash equivalents, and investment assets of $351.3 million reduce short-term funding risks by supporting the pivotal trial for schizophrenia and the Phase 2 VISTA trial for Alzheimer's disease-related psychosis through the end of 2028. In the $9.08 billion schizophrenia drug market in 2025, BMY's marketed Cobenfi and Neurocrine's Phase 3 Direclidine have established commercial and development benchmarks. The discontinuation of early-stage pipeline programs increases cash efficiency but also increases dependence on ML-007C-MA, making the results of the FDA meeting, the design of the pivotal trial, and compliance with the twice-daily regimen key determinants of long-term value.